Richard H.  Scheller net worth and biography

Richard Scheller Biography and Net Worth

Chairman of the Board of DICE Therapeutics

Richard Scheller became chairman of the board at DICE Therapeutics in 2015. Richard had joined 23andMe in January 2015 as chief scientific officer and head of therapeutic development. There, he is responsible for translating genetic information into new therapies.

Hired in 2001 as senior vice president of research and member of the Genentech Executive Committee, from 2009 through 2014, he was executive vice president and head of Genentech Research and Early Development, and a member of the Roche Executive Committee. He received his B.S. in biochemistry in 1975 from the University of Wisconsin–Madison and his doctorate in chemistry in 1980 from Caltech. After postdoctoral fellowships at Caltech and Columbia, Richard joined the Stanford faculty from 1982 until 2001. An investigator with the Howard Hughes Medical Institute from 1994 to 2001, Richard has ­been an adjunct professor at UC San Francisco since 2004. In 2014, he was named a trustee of Caltech.

Richard’s research elucidating molecular mechanisms governing neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He is a fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Sciences and the National Academy of Medicine.

What is Richard H. Scheller's net worth?

The estimated net worth of Richard H. Scheller is at least $400.70 thousand as of May 5th, 2023. Dr. Scheller owns 8,427 shares of DICE Therapeutics stock worth more than $400,704 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Scheller may own. Learn More about Richard H. Scheller's net worth.

How do I contact Richard H. Scheller?

The corporate mailing address for Dr. Scheller and other DICE Therapeutics executives is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. DICE Therapeutics can also be reached via phone at 650-566-1420 and via email at [email protected]. Learn More on Richard H. Scheller's contact information.

Has Richard H. Scheller been buying or selling shares of DICE Therapeutics?

Richard H. Scheller has not been actively trading shares of DICE Therapeutics during the last quarter. Most recently, Richard H. Scheller sold 84,097 shares of the business's stock in a transaction on Friday, May 5th. The shares were sold at an average price of $38.51, for a transaction totalling $3,238,575.47. Following the completion of the sale, the director now directly owns 8,427 shares of the company's stock, valued at $324,523.77. Learn More on Richard H. Scheller's trading history.

Who are DICE Therapeutics' active insiders?

DICE Therapeutics' insider roster includes Kevin Judice (Co-Founder & CEO), Richard Scheller (Chairman of the Board), and James Scopa (Director). Learn More on DICE Therapeutics' active insiders.

Richard H. Scheller Insider Trading History at DICE Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/5/2023Sell84,097$38.51$3,238,575.478,427View SEC Filing Icon  
See Full Table

Richard H. Scheller Buying and Selling Activity at DICE Therapeutics

This chart shows Richard H Scheller's buying and selling at DICE Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DICE Therapeutics Company Overview

DICE Therapeutics logo
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $47.55
Low: $47.55
High: $47.55

50 Day Range

MA: $47.31
Low: $46.62
High: $47.55

2 Week Range

Now: $47.55
Low: $15.08
High: $47.90

Volume

N/A

Average Volume

1,028,719 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03